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Human Immunodeficiency Virus (HIV) incorporates a number of host proteins. These 
proteins can provide information on the function of viral proteins, as well as on the 
general process of HIV biogenesis. Determining the methods of incorporation and 
potential functional importance will help advance our knowledge of the HIV lifecycle 
and holds the potential to produce additional targets for antiretroviral therapy. Here, we 
used a variety of complementary techniques to determine which host proteins are 
incorporated into HIV particles. We found that most of the CD28 and B7 family 
costimulatory molecules are excluded from viral particles. Using a novel purification 
technique and mass spectrometry analyses, we were able to characterize host protein 
incorporation in HIV particles derived from CD4+ T-cell lines; we compared this data set 
to a reprocessed data set of monocyte-derived macrophages derived HIV-1 using the 
same bioinformatics pipeline. Seventy-nine clustered proteins were shared between the 
data sets. These clusters included an extensive collection of actin isoforms, HLA 
proteins, chaperones, ERM proteins, EH4, a phosphodiesterase, cyclophilin A, and 
others. As these proteins are incorporated in virions produced in both cell types, we 
hypothesize that these proteins may have direct interactions with viral proteins or may be 
important in the viral lifecycle. Additionally, this common protein set protein is predicted 
to interact with >1000 related proteins. Many of these secondary interacting proteins are 
reported to be incorporated into virions. Thus, only a few direct interactions between host 
and viral proteins may drive host protein composition in virions. We hypothesized that 
these may be driven by the tetraspanin family of proteins, putative membrane organizers 
determining the lipid and protein composition of tetraspanin enriched membranes. We 
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found that knockdown of various tetraspanins in T cell lines did not significantly alter 
viral release or phenotype. Ultimately, cell type-specific differences in host protein 
interaction and expression may drive virion phenotypic diversity, despite conserved 
primary viral protein-host protein interactions across cell types. Further, the primary 
interactions found between viral and host proteins are likely driven by selective pressures 
including response to host restriction factors and membrane structural requirements. 
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Acquired Immunodeficiency Syndrome (AIDS) is one of the most devastating infectious 
disease epidemics in recorded human history, with an almost 35 million people estimated 
to have died from the disease. Further, an estimated 70 million people are believed to 
have been infected with Human Immunodeficiency Virus (HIV)-1 and -2, the virus that 
causes AIDS. Worldwide, there are approximately 34 million people living with HIV.1 
This epidemic, now 30 years old, continues to progress around the world, despite the fact 
that HIV infection is entirely avoidable and prevention methods have been known for 
almost the entire duration of the epidemic. 
 
The HIV epidemic has also fostered one of the most significant scientific efforts in 
modern history, with the last 30 years of research on the scale equal to the development 
of atomic energy, manned space flight or the polio vaccination initiative. HIV research 
has produced an equally impressive result: the development of life-saving antiretroviral 
therapy. Antiretrovirals are now commercially available in several classes; 
nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse 
transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors, chemokine 
antagonists, and integrase strand transfer inhibitors (INSTIs). Notably, even though HIV 
requires a large number of cellular proteins to efficiently replicate, almost all of these 
options target viral proteins. 
 
The 10kb HIV-1 genome encodes for 16 proteins, which are derived from the primary 
retroviral genes gag, pol, and env, and the accessory protein genes tat, rev, nef, vpr, vpu, 
and vif. In general, the accessory proteins serve to enhance viral replication, either 
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completing a vital step in viral lifecycle or by modulating the cellular environment to 
allow for greater replication. The rev protein is responsible for the transport of singly 
spliced or unspliced viral RNA transport to the cytoplasm.2 Tat and nef are important for 
high levels of viral replication.3,4 Vif binds the cytadine deaminase APOBEC3G and vpu 
binds tetherin, both interactions allowing for viral replication.5,6 Vpr is involved in 
nuclear integration of the HIV pre-integration complex, cell cycle arrest, host-cell 
apoptosis, and immune suppression induction.7-12 Notably, many of these proteins have 
been reported to have multiple functions, underscoring the complexity of HIV biology. 
 
Antiretroviral therapy targets the classical retroviral proteins. NRTIs and NNRTIs inhibit 
reverse transcriptase, either through chain termination or active site inhibition. PIs inhibit 
protease function and, thus, proper formation of the viral core following viral budding. 
INSTIs prevent integration of the proviral DNA into the host genome. Fusion inhibitors 
bind the gp41 subunit of the viral envelope protein and prevent viral entry. CCR5 
agonists prevent binding of the envelope protein to the CCR5 receptor and, therefore, 
block viral entry.13 
 
While viral proteins are essential for proper viral replication, many host proteins are also 
involved in HIV replication. This has been demonstrated in viral budding, a complex 
process involving the co-ordination of many cellular and viral proteins.14,15 Host proteins, 
such as the ESCRT family of proteins, proteins involved in ubiquitination, and proteins 
involved in proteasome function, have been shown to function in HIV budding.16-18  
Many of these proteins are also involved in the formation of exosomes, small vesicles 
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that bud into multivesicular bodies and are released from the cell.19-24  Host proteins 
ensure that viral proteins reach their target membranes, allowing for formation of the 
nascent virion. HIV buds from lipid ordered domains (or detergent resistant membranes); 
targeting to this region of the cell membrane is dependent on the gag protein.25-29 The 
HIV “lipidome” reflects budding from these regions. Brugger and colleagues 
quantitatively analyzed the lipid composition of producer cells and the progeny virus in 
the absence of detergent, finding that HIV-1 virions had similar composition to detergent 
resistant membranes and were enriched for lipids including cholesterol, sphingomyelin 
and dihydrosphingomyelin, plasmenylethanolamine, monohexosylceramide, saturated 
phosphatidyl choline species, and phosphotidyl serine.30 The concentration of cholesterol 
and sphingolipids in these regions result in a tightly packed, ordered structure that is 
resistant to disruption by non-ionic detergents at low temperature.31-33 
Immunomicroscopy studies show that gag and viral envelope proteins colocalize with 
lipid raft markers on the surface of infected cells.26,29 Proteins on the cytoplasmic side of 
the membrane, such as src family proteins and alpha subunits of G-proteins, are directed 
to these regions by the post translational addition of acyl groups; primarily myristylation 
or palmitylation.34-36 Myristolation of the matrix domain of gag targets the protein to 
these regions.28,37-40 In liposomes, gag strongly localizes to lipids with both acyl chains 
unsaturated over those with only one chain unsaturated. Cholesterol in the membrane 
region also leads to increased gag binding and closer phospholipid packing.41 Interactions 
between gag and the cytoplasmic domain of env regulate the incorporation of the viral 
spike in the viral envelope.42-48 It has also been reported that nef is involved in enriching 
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sphingomyelin and reducing polyunsaturated phosphatidylcholine species in the viral 
envelope.49 
 
Budding from these domains appears to be crucial for the viral lifecycle. Several groups, 
including ours, have demonstrated that removal of cholesterol—a critical component of 
lipid ordered domains—from HIV particles results in inactivation. This appears to occur 
due to a loss of the ability to fuse to the target cell and the loss of virion integrity 
resulting in permeabilization of the virus.50-56 While HIV has been shown to bud from 
detergent resistant membranes, the exact nature of the membranes is still unclear. For 
example, HIV has been shown to bud from “lipid rafts”, but it has also been shown to 
bud from similar structures, tetraspanin enriched membranes (TEMs). While these two 
lipid ordered domains share many similarities, they are distinct membrane domains. 
However, Hogue and colleagues recently determined that the presence of gag induces the 
coalescence of lipid rafts and TEMs, and that this may be in a stepwise fashion.57 
 
Further, the viral envelope presumably reflects the budding point, with the incorporation 
of many proteins found in detergent resistant membranes and the exclusion of proteins 
that do not localize to these domains.26,58 These regions’ rafts are highly enriched in GPI-
anchored proteins, and generally exclude E cadherin and CD45.59,60 A large number of 
proteins have been reported to be incorporated into the viral envelope, and these proteins 
belong to a number of different families or functional groups. For example, proteins 
involved in the immune response, including HLA molecules and some costimulatory 
molecules, are found in the viral envelope. Adhesion molecules, such as ICAM-1 and 
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LFA-1, are also reported to be in the viral envelope, as are cytoskeletal proteins, 
including actin. A short and incomplete list of proteins reported to be in the viral 
envelope includes annexin 2, Thy-1, CD44, CD46, CD55, CD59, CD63, and CD71. 
While many proteins have been reported to be incorporated into the viral envelope, it is 
important to consider that it is unlikely that all of these proteins are always incorporated 
into every viral particle. Thus, the host protein composition is likely to be heterogeneous, 
probably even between virions produced in the same cell. This is almost certainly the 
case for virions produced from different cell types. It is also important to note that these 
host proteins are not selected for in the viral envelope due to abundance in the plasma 
membrane—they are specifically enriched in lipid ordered domains.58,61,62 
 
HIV-1 host protein incorporation is not just limited to membrane proteins. Cyclophilin A 
(CypA) has long been known to be incorporated into HIV-1 virions, facilitating HIV 
replication.63-65 Notably, polymporphisms in CypA have been shown to affect disease 
progression.66 Host proteins in the viral envelope may also affect HIV biology; virions 
incorporating the adhesion molecules LFA-1 and VLA-4 can have increased infectivity.67 
Thus, host protein incorporation can potentially affect disease course. 
 
Here, we investigated host protein incorporation into the HIV virion, with an emphasis on 
membrane proteins that may have functional consequence, either on immune function or 
membrane fission/fusion. We also used proteomic analysis to identify common 
incorporated host proteins in HIV regardless of progenitor cell type. We believe the 
findings have implications on the method of host protein incorporation and provide a 
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HUMAN IMMUNODEFICIENCY VIRUS-TYPE 1 DOES NOT INCORPORATE 






HIV is known to incorporate many of the molecules found in the immunologic synapse, 
including adhesion and MHC class proteins. Lipid ordered domains have been shown to 
be important in the formation of the immunologic synapse;68 HIV has also been shown to 
bud from lipid ordered domains.26-28,54 Based on host molecule location, we hypothesized 
that HIV would incorporate costimulatory molecules, which are found in the 
immunologic synapse. 
 
Esser and colleagues showed in 2001 that HIV derived from macrophages include CD80 
(B71) and CD86 (B72), with CD86 incorporated in greater quantities.69 However, a 
number of other B7 family members were discovered in macrophages around this time.70 
These include ICOS (Inducible T-cell Costimulator), PD-1 (Programed cell Death protein 
1), PD-L1 (Programmed Death Ligand 1; B7-H1), PD-L2 (B7-H2), B7-H3 and B7-H4.  
Using an antibody against CD152 (CTLA-4), one group has been able to 
immunoprecipitate HIV-1 produced in Jurkat cells transfected with CD152. They were 
also able to immunoprecipitate HIV-1 with anti-CD28 and could block infectivity with 
antibodies directed against either of the CD28 family members.71 
 
Costimulatory molecules of the B7 and CD28 families have important roles in regulating 
T cell activation, inhibition, and cytokine release profiles. HIV also infects CD4+ T cells 
and incorporates several of the host molecules found in the immunologic synapse in these 
cells. As prior studies had not investigated the potential for incorporation of then newly-
discovered costimulatory proteins from CD4+ T cells, we endeavored to determine if 
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HIV indeed incorporates these molecules into the viral envelope. Further, we have also 
looked at the incorporation of host costimulatory molecules in the viral envelop for HIV-
1 produced in both T cell lines and monocyte derived macrophages (MDM). As 
interaction of costimulatory molecules on with their cognate receptors on T cells results 
in signaling events that regulate immune responses, including the balance between Th1 
and Th2 responses, it would be of interest if HIV incorporated costimulatory molecules in 
the viral envelope. This could have functional impacts and potentially impact disease 
progression.72,73 Therefore, we investigated the incorporation of CD28 family members 
(CD28, ICOS, CD152 and PD-1) and well as B7 family members (CD80, CD86, B7-H1, 
B7-H2, B7-H3, and B7-H4). We have confirmed the incorporation of CD86 in virions 
produced in MDM, but were unable to confirm the incorporation of any other CD28 or 





Materials and Methods 
Viral stocks. Viral stocks were produced in chronically infected CD4+ T cell lines or 
primary MDMs. HIVMN was produced in H9 cells; HIVRF was produced in Jurkat cells 
and PM1 cells. Supernatant was depleted of microvesicles using CD45-coated 
paramagnetic beads (Dynal). Viral stocks were then pelleted through a 20% sucrose 
gradient at 100,000 x g for 1 hr and 15 minutes. Direct-pelleted BaL produced from 
MDM was purchased from ABI. Viral p24 content was assayed by ELISA, as previously 
described.55  
 
Cell culture. All cells were propagated in RPMI supplemented with 10% FBS (HyClone), 
100 μg/ml streptomycin, and 100 U/ml penicillin. 
 
Immunoprecipitation. Viral particles were precipitated using Staphylococcus aureus 
Cowan strain (SaC; zysorbin). Primary antibodies were diluted in 3% BSA/PBS to 10 
ug/mL. Viral stocks were diluted to 20-40 ng p24/mL. 100 µL diluted Ab and 100 µL 
diluted virus were incubated on ice for 60 minutes. Rabbit anti-mouse (RaM) IgG, Fc 
gamma fragment specific antibody was diluted to 1 mg/mL in 3% BSA/PBS. For each 
sample, 50uL SaC and 10 µL RaM were incubated on ice for 30 minutes. 60 uL 
SaC/RaM was added to each sample of virus/primary antibody and mixed on ice for 60 
minutes. Samples were spun at 2700 RPM at 4ºC for 7 minutes. Supernatant was saved 
for analysis. The SaC/sample mixture was washed 2-times with 3 mL 10X PBS and one 
time with 1X-PBS. Each sample was lysed with 700 µL lysis buffer (TEN pH 8.0, 1% 
triton X-100) and incubated on ice for 45 minutes. SaC was pelleted at 32,000 RPM for 2 
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minutes and 650 µL of supernatant was saved. Remaining SaC from the supernatant was 
pelleted and 600 µL of supernatant was saved for analysis. Supernatant was serial diluted 
(1:2) and plated for analysis by HIV p24 ELISA. 
 
HIV p24 ELISA. GagM1 (Leukocyte Immunochemistry Laboratory; LIL) antibody was 
diluted to 10 µL/mL n 50 mM TRIS pH 9.5. For each well of CoStar Fast binding ELISA 
plates, 100 µL of diluted GagM1 antibody was added and plates were incubated 
overnight at room temperature. Antibody was removed and 200 µL 3% BSA/PBS was 
added to each well. Plates were incubated 2 hours at 37ºC. Plates were washed 8-times 
with PBS/0.05% Tween 20. p24 standards were diluted to 1000, 250, 125, 62.5 and 31.2 
pg/mL in standard antigen dilution buffer (RPMI-1640, 10% FCS, 1.0% Triton X-100). 
100 uL of sample per well was added to the plates in triplicate, along with p24 standards. 
Plates were incubated overnight at room temperature and then washed 8-times with 
PBS/0.05% Tween 20. Biotinylated anti-p24 polyclonal IgG was added to each well (100 
µL at 0.1 mg/mL) and incubated for 2 hours at room temperature. Plates were washed 8-
times with PBS/0.05% Tween 20. 100 uL of streptavidin-peroxidase (1:10,000 in 5% 
NGS, 1% BSA, PBS, 0.05% Tween 20) was added to each well and incubated for 30 
minutes at room temperature. Plates were washed 8-times with PBS/0.05% Tween 20. 
100 µL of substrate (10 ml Na Acetate/Citrate, 100 µL TMB, 5 µL H2O2) was added to 
each well and incubated for 20 minutes at room temperature. The reaction was stopped 





Flow Cytometry. Flow cytometry was performed by first fixing cells with phosphate-
buffered saline (PBS) containing 2% paraformaldehyde and then permeabilizing cells 
with PBS buffer containing 1% BSA, 5% normal goat serum (NGS), and 0.2% saponin, 
followed by staining with appropriate antibodies (Abs). Infection of cells was determined 
by flow cytometry using fluorescein isothiocyanate (FITC)-conjugated anti-p24 
(Coulter). The primary MAbs were detected with Alexa Fluor 647-conjugated goat anti-
mouse polyclonal antibody. Virus production was measured by anti-p24 gag enzyme-
linked immunosorbent assay (ELISA). Compensation was performed with single-stained 
cells. Data were collected on FACSCalibur (BD Biosciences) instruments and analyzed 
with FACSDiva (BD Biosciences) or Flowjo (Tree Star) software. For 
immunofluorescence staining, cells were fixed with 2% paraformaldehyde in PBS and 
permeabilized with PBS containing 5% NGS, 1% BSA, and 0.25% Triton X-100. Cells 
were than stained with indicated primary and secondary Abs. At the time of viral 
production, flow cytometric analyses were conducted to determine the phenotype of cells 
used to produce virus. A minimum of 10,000 cells were run on a Beckton Dickenson 
FACScaliber. 
 
Flow cytometric based analysis of HIV phenotype. Viral and microvesicle membranes 
were labeled with the fluorescent dye PKH67 as follow. Virus/microvesicles (10 μg total 
protein) was resuspended in 1 ml of diluent C in an ultracentrifuge tube and mixed with 
PKH67 in diluent C (final concentration 5x106 M) and incubated for 3 min. The 
ultracentrifuge tube was filled with 0.1% BSA/PBS and spun for 65 minutes at 100,000 × 
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g. Samples were washed twice in 0.1% BSA/PBS and resuspended in 250 ul 0.1% 
BSA/PBS. Total protein was quantified by BCA assay. 
 
Beads were prepared as follows: 25 µL anti-mouse IgG beads were incubated with 5 µL 
primary Ab in 0.1% BSA/PBS in total volume of 50 µL and rotated overnight at 4º C. 
Beads were washed twice with 0.1% BSA/PBS (2-3mL). Beads and antibodies were 
cross-linked with 2% PFA for 15 minutes at room temperature and then washed with 
0.1% BSA/PBS. Beads were blocked in 5% NMS/PBS (15 minutes at room temperature) 
and then washed with 0.1% BSA/PBS. Beads were resuspended in 100 µL 0.1% 
BSA/PBS. 
 
Conjugated beads (2 µL) were incubated with virus/microvesicles (10 µg total protein) in 
total volume of 20 µL and rotated for 2 hours at room temperature. Beads were washed 2-
times with 0.1% BSA/PBS. Beads were incubated with 50 µL PFA at room temperature 
for 15 minutes and washed twice with 0.1% BSA/PBS. Virus/microvesicles were 
incubated with 1 µg anti-gp41-biotin in a total volume of 50 µL (5% NMS), rotated in the 
dark for 1 hour at room temperature. Samples were then washed with 0.1% BSA/PBS and 
incubated with 10 µL SA-PE for 45 minutes in dark at room temperature. Samples were 
washed twice with 0.1% BSA/PBS and resuspended in 250 µL 2% PFA for 15 minutes, 
washed, and then 250 µL 0.1% BSA/PBS. Samples were then analyzed on a 





Producer cell lines contain costimulatory molecules 
Phenotyping cell lines by flow cytometry, we observed high levels of CD45, CD152, and 
B7-H2 in multiple different T cell lines, both uninfected and chronically HIV-1 infected 
(Figure 2-1). Lower levels were seen for CD80, ICOS, B7H1, and PD1. We also saw 
significant shifts in mean fluorescent intensity (MFI) in chronically infected T cell clones 
(Figure 2-2). MFI shifts were observed in at least one cell type studied for all 
costimulatory molecules assessed. Thus, there was sufficient evidence to support 
phenotyping of viral particles for these costimulatory molecules. 
 
HIV-1 virions do not incorporate most costimulatory molecules 
We then assessed incorporation of costimulatory molecules and control molecules in 
HIV-1 virions. As shown in Figure 2-3, we immunoprecipitated virions with primary 
antibodies against B7-H1, B7-H2, B7-H3, B7-H4, ICOS, B7RP1 (ICOS ligand), CD80, 
CD86, CD152, and PD-1. We also used the positive controls gp41 and HLA A/B/C and 
the negative controls IgG1 (isotype control) and CD45. We saw no incorporation above 
the negative controls for almost all molecules studies, except for CD86, which was 
present in virions produced from MDMs. We also compared molecule incorporation to 
host cell expression for each marker (Figure 2-4). While costimulatory molecules were 
expressed in many cases, we were not able to immunopreciptate viral particles using 
antibodies against these costimulatory molecules. Notably, antibodies against positive 
controls, HLA molecules and gp41, were able to immunopreciptate virions. 
16 
 
Figure 2-1. Expression of select costimulatory markers in uninfected controls or 
chronically infected cell lines.  
Cell lines were assessed for costimulatory molecule expression by flow cytometry. The 
percent of positive cells are indicated. Isotype controls (IgG1) and phenotype controls 










Figure 2-2. Expression of costimulatory markers in chronically infected cell lines.  
Cell lines were assessed for costimulatory molecule expression by flow cytometry. 










Figure 2-3. Incorporation of costimulatory molecules into HIV-1 virions produced 
in chronically infected T cells or MDMs. 
Virions from H9/HIVMN, Jurkat/HIVRF, PM1/HIVRF, and MDM/HIVBaL were 
immunoprecipitated with antibodies against multiple costimulatory molecules or control 








Figure 2-4. Costimulatory molecule incorporation compared to cellular expression. 
Incorporation of costimulatory molecules was compared to the producer cell expression 








In order to further confirm the presence or absence of host-derived surface markers on 
HIV virions, we developed a novel flow cytometry-based assay to phenotype viral 
particles. In this assay, virions were labeled with the fluorescent membrane dye PKH67 
and immunoprecipitated with microbeads specific for membrane proteins. The beads 
were then run through a flow cytometer, with the FITC channel showing the amount of 
microvesicles attached to the microbeads. In order to rule out microvesicle 
contamination, the microvesicle coated microbeads were incubated with an anti-gp41-PE 
antibody. Thus, FITC- and PE-positive populations represented viral particles, while 
FITC-only populations represented microvesicles (Figure 2-5). 
 
As shown in Table 2-1, we were unable to effectively discriminate between viral particles 
and microvesicles using this method. However, we were able to capture and assess the 
FITC+ population, representing both microvesicles and virions. We observed 
significantly higher FITC levels when capturing using HLA A/B/C, CD81, or CD45 
compared to isotype controls. We were unable to see significant differences in capture 





Figure 2-5. Schematic of a novel flow-based phenotyping method to distinguish 
microvesicles from virions in mixed samples. 
Microbeads were coated with a pan anti-mouse IgG, which was then conjugated to a 
mouse anti-human primary antibody. Microvesicles and HIV virions were labeled using 
the membrane dye PKH67. Microvesicles and virions were immunopreciptated and 
further mixed with anti-gp41-PE. Samples were analyzed by flow cytometry, gating on 
bead populations. FITC-positive, PE-negative populations are indicative of 




















IgG 99.63 0.03 0.29 0.06 
HLA A/B/C 46.39 0.05 53.48 0.08 
CD81  27.45 0.05 72.42 0.08 
CD45  50.69 0.00 49.25 0.05 
CD152 (BD)  98.51 0.05 1.43 0.00 
CD152 (LIL) 99.11 0.02 0.85 0.02 
CD80 97.05 0.05 2.21 0.69 







Here, we did not find evidence supporting the incorporation of most known costimulatory 
molecules in the viral envelope. It has previously been reported that CD80 and CD86 are 
incorporated into the viral envelope, with CD86 incorporated to a greater degree than 
CD80.69 Our data supports this prior observation. However, other B7 family members, 
including B7-H1, B7-H2, B7-H3, and B7-H4, were not observed in the viral envelope. 
 
We also did not find any evidence for incorporation of CTLA-4 in the viral envelope. 
This is notable considering the incorporation of CTLA-4 in the viral envelope has been 
published in the Journal of Infectious Diseases.71 Given that CTLA-4 incorporation has 
been published in a peer reviewed journal, we tried to assess incorporation under 
different conditions and with several techniques. Using a standard immunoprecipitation 
technique with Staphylococcus aureus protein A as the precipitant, we were unable to 
pull down significant amounts of virus with three separate CTLA-4 antibodies (one 
commercial and two developed in our laboratory). This was true for many viral strains 
produced in many different cell lines. Further, we were unable to find any evidence of 
CTLA-4 incorporation in virus produced from activated PBMCs (data not shown) or in 
commercially-purified virus produced from MDMs. Western blots of concentrated lysed 
viral stocks also failed to show any evidence of CTLA-4 or other costimulatory markers 
(data not shown). We were unable to confirm CTLA-4 in the viral envelope in viral 
stocks produced from 293T cells cotransfected with proviral clones and CTLA-4 
expression plasmids (data not shown). Finally, using a novel flow cytometry-based assay, 
we were also unable to detect the presence of CTLA-4 in the viral envelope or in 
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microvesicles. Additionally, proteomic analyses of host proteins in HIV virions have not 
detected the presence of CTLA-4 or any other costimulatory molecules (see Chapter 
III).74 These data together very strongly indicate that, contrary to the published literature, 
CTLA-4 is not incorporated to any significant degree in the viral envelope. 
 
The lack of CTLA-4 and other costimulatory markers in the viral envelope has some 
significant implications on hypotheses that HIV can function as an antigen presenting 
cell. HIV has been shown to incorporate a number of proteins that are found in the 
immunologic synapse, including MHC molecules, CD86, and ICAM.69,75-77 The 
incorporation of adhesion molecules has been shown to have a functional significance for 
the virus, aiding in attachment to cell membranes.67 The inclusion of MHC molecules has 
been suggested to potentially serve as one signal for the activation of CD4+ cells by HIV. 
As HIV infects actively replicating CD4 cells, activation of quiescent cells upon viral 
attachment would have the potential to be beneficial for the virus. Further, as MHC 
molecules in the viral envelope would likely have viral antigen in their clefts, HIV would 
be posited to preferentially infect HIV-specific T cells. This has been shown to be the 
case by Douek and others.78-80 However, this line of reasoning requires that the HIV 
envelope contains molecules capable of delivering a costimulatory signal. For the 
activation of T cells, this would require CD80 or CD86, both of which are incorporated to 
varying degrees in the viral envelope.69 In 2004, Giguere and colleagues reported that 
inclusion of CD80 or CD86 in the viral envelope results in NF-κB induction, supporting 
this hypothesis.81 This same group has suggested that HIV acts as an antigen presenting 
cell, which may help explain preferential infection of HIV-specific CD4+ T cells.82 
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Activation induced by host proteins incorporated in the viral envelope could have a 
significant effect on HIV pathogenesis, as chronic activation is proposed to result in 
immune exhaustion and the development of AIDS in people with uncontrolled HIV 
infection.83 However, activation or suppression effects that may be predicted from the 
incorporation of other B7 or CD28 family members in the viral envelope are unlikely, 
due to their lack of inclusion in virions produced in either lymphocytes or monocytic 
cells. 
 
The lack of CTLA-4 in the viral envelope has some additional significance. One of the 
primary features of HIV infection is an increase in anergic T cells. One mechanism of T 
cell anergy is though the B7-CTLA-4 interaction. In this interaction, there is an inhibitory 
signal cascade sent through CTLA-4 in T cells, which prevents continued activation of 
cells. However, there is also a corresponding signal cascade in monocytic cell lines 
though B7 molecules, which induces tryptophan metabolism and results in localized 
micronutrient depletion. This induces an anergic response in T cells surrounding the 
monocytic cell.72,73 While we originally hypothesized that HIV-1 virions might be 
capable of inducing anergy upon incorporation of CTLA-4 in the viral envelope, it 
appears that this is not the mechanism. 
 
HIV has been shown to affect costimulatory expression within cells infected with HIV or 
chronic infection with other viruses. For example, LCMV-infected mice show 
upregulated PD-1 and CD152 in exhausted cells. Notably, blockade of PD-1 interaction 
with one cognate ligand, B7-H1 (PD-L1), restores CD8+ T cell function in these mice.84 
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Similarly, PD-1 is upregulated in chronic HIV infection, with similar impacts on CD4 
and CD8 responses.85,86 Accordingly, blockade of this interaction has been suggested a 
potential therapeutic target in chronic viral infections.87-89 CD152 has also been shown to 
be upregulated in HIV and SIV infection, which has been suggested to lead to increased 
tryptophan catabolism and associated anergy.90,91 Moreover, HIV-specific T cells show 
CD152 upregulation and this correlates with immune dysfunction in HIV-positive 
subjects.92 Further, B7-H1 has been shown to be upregulated in HIV infection, while 
CD86 is downregulated, which could produce similar inhibitory effects.93,94 While 
changes in costimulatory molecule expression can—and likely are—a mechanism of 
immune dysfunction in HIV and other chronic viral infections, it is unlikely that these 
changes are resultant from any inclusion of costimulatory molecules in the viral 
envelope. 
 
We investigated a number of different viral strains and different cell type, which has 
importance as the host protein composition in the viral envelope can vary depending on 
the viral strain and cell type.75,95,96 This intuitively makes sense, as changes in viral 
genetic sequences and corresponding protein changes have the potential to affect host-
viral protein interactions. Incorporation may be impacted by producer cell differences in 
costimulatory molecule localization. Of particular note, while MHC molecules and 
costimulatory molecules are localized to lipid ordered domains in both CD4+ T cells and 
monocytic cells, MHC Class II and CD28 family member localization in CD4+ cells is 
found at sites of antigen presenting cell (APC)-T cell interaction, while MHC Class II 
and B7 family member localization is not polarized in monocytic cells.97,98 This may 
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account for the observed lack of costimulatory molecule inclusion in virions purified 
from cell culture supernatant in CD4+ T cells. It is possible that HIV may be capable of 
incorporating CD28 family members in vivo, but these virions would bud directly into an 
engaged immunologic synapse and, therefore, may not be found to a significant degree in 
circulation. 
 
Additionally, the host-viral interactions will likely depend on the protein composition of 
the producer cell; however, it appears that some host proteins are incorporated into HIV 
virions regardless of producer cell type.96 This aspect of host-viral protein interactions 
and resultant host protein incorporation is further explored in the next chapter “The 
conserved set of host proteins incorporated into HIV-1 virions suggests a common egress 








THE CONSERVED SET OF HOST PROTEINS INCORPORATED INTO HIV-1 
VIRIONS SUGGESTS A COMMON EGRESS PATHWAY IN MULTIPLE CELL 
TYPES 
 
The work contained in this chapter has been published previously in: 
Linde ME, Colquhoun DR, Mohien CU, Kole T, Aquino CV, Cotter R, Edwards N, Hildreth JE, Graham 
DR. The conserved set of host proteins incorporated into HIV-1 virions suggests a common egress pathway 





During HIV replication and packaging, HIV relies on the coordinated interactions 
between viral and host proteins.99 As HIV buds, it incorporates hundreds of cellular host 
proteins into the nascent virion, either into its lipid bilayer or inside the HIV 
virion.74,76,100 Several studies have indicated that host protein incorporation affects both 
HIV attachment and infectivity.67,101 Other proteins, such as cyclophilin A, have been 
implicated in the HIV lifecycle;63-65,67,76 however, due to the large number of host 
proteins reported to be incorporated into HIV virions, it is difficult to determine the 
biological relevance, if any, of many of these proteins. 
 
We hypothesized that host proteins that play a significant role in the HIV-1 virion 
lifecycle or those that significantly affect HIV spread through the host would be 
conserved in the virus regardless of the progenitor cell type. HIV-1 infects multiple cell 
types, most prominently macrophages and CD4+ T cells. As these cell types have 
different protein expression patterns and surface protein composition, it is expected that 
HIV-1 virions budding from these different cell types carry different sets of host proteins. 
Further, it is likely that many of the proteins incorporated by the virus are done so 
through secondary or higher interactions. Here, we define a minimal set of relevant host 
proteins that are incorporated into HIV-1 virions from multiple cell types. 
 
Mass spectrometry (MS) analysis of purified viral particles is one tool for determining 
which host proteins are incorporated in HIV virions on a global scale. While there are 
biochemical and proteomic techniques that can be used to identify HIV-associated 
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proteins, the success of these studies are limited by HIV purification techniques that often 
result in co-purification of contaminating microvesicles.102,103 HIV virions are small, 
dense particles of approximately 100 nm in diameter;  HIV-infected cells produce 
microvesicles of similar size and density to that of the HIV virion, which have also been 
shown to share many of the components of HIV.58 A variety of techniques have been 
employed to reduce microvesicle contamination, including CD45 depletion of 
microvesicles and affinity purification using viral envelope proteins.104 Due to the large 
quantities of virions needed, affinity purification of virions or depletion of microvesicles 
is not a practical option for many biochemical studies. Therefore, we developed a novel 
strategy for purifying large quantities of HIV-1. By using cholesterol to manipulate the 
density of the particles in HIV-1 preparations (density modification; DM), we were able 
to separate virions from contaminating vesicles by centrifugation, making them suitable 
for analysis by tandem MS. Using this strategy, we were able to characterize host protein 
incorporation in HIV particles derived from CD4+ T cell lines. We compared our DM 
purification method with an orthogonal purification approach using inoxidol (OptiPrep) 
gradients by quantitative proteomics. Lastly, we tested our hypothesis that conserved 
proteins would reveal critical shared pathways by comparing our dataset of T cell derived 
HIV-1 virions to a reprocessed dataset of monocyte-derived macrophages (MDM) 
derived HIV-1 using the same bioinformatics pipeline.  
 
We identified clusters of conserved proteins between MDM and T-cell derived HIV-1. 
These clusters included an extensive collection of actin isoforms and other core 
interacting proteins, many of which have previously been documented to interact with 
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viral proteins.105,106 These data suggest that a limited number of viral-host protein 
interactions can explain the phenotypic diversity of HIV-1 virions produced from MDM 
or T-cells allowing HIV-1 to be incredibly plastic and opportunistic in its final protein 
composition depending on the cell type it is produced from. The common incorporation 
of syntenin-1 (a component of tetraspanin enriched membranes, TEMs) and CD44 
(hyaluronic acid receptor) is suggestive of a common cellular egress pathway involving 






Materials and Methods 
Apparatus. MALDI-MS and MS/MS spectrum were obtained using an ABI 5800 MALDI 
TOF/TOF analyzer (AB Sciex) using a 2KeV extraction method with CID turned off 
using dynamic exit. 
 
Reagents. HIVMNCl.4 from either H9 (T-cell line) or CEMx174 (B-cell/T-¬cell hybrid 
line) cells was obtained from the AIDS and Cancer Vaccine Program (SAIC-Frederick). 
 
Virus purifications. DM purification was accomplished by incubating virus in 420 µg/ml 
of cholesterol and 20 mM 2-hydroxy-beta cyclodextrin (βCD) in TNE as indicated, 
filtration through a 5 um filter on ice and pelleted through 20% sucrose for 1h at 100K x 
g. OptiPrep purification was performed as previously described.107 SDS page, western 
blotting and EM were performed as described.55  
 
Quantitative MS. Virus (normalized by p24) was ultracentrifuged and resuspended in 0.5 
M triethylammonium bicarbonate with 1% rapigest, reduced (TCEP) and alkylated 
(MMTS) and subjected to tryptic digestion as previously described.108 Peptides were 
labeled with iTRAQ reagents as follows for HIV-1 derived from CEMx174 cells: m/z 
113: Control, m/z 114: DMP, m/z 115: OptiPrep, and for HIV-1 derived from H9 cells: 
m/z 117: Control, m/z 118: DMP, m/z 115: OptiPrep. Peptides were then subjected to 
nano rHPLC on a TEMPO-LC MALDI spotting system using a 90 minute gradient from 
5% to 80% B (98 % ACN, 0.1 % TFA) at 500 nl min-1, Matrix (CHCA, 5 mg / mL in 75 
% ACN) was then supplemented to the flow post-column at 500 nl min-1, and samples 
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were deposited onto a stainless steel plate at 10 second intervals. 1000 MALDI-MS and 
up to 1500 MS/MS spectrum were obtained using an ABI 5800 MALDI TOF/TOF 
analyzer (AB Sciex) using a 2KeV extraction method with CID turned off using dynamic 
exit.  Spectral quality settings were set to high for both the spectrum and the iTRAQ 
reporter regions, according to manufacturer’s suggestions (AB Sciex).   ProteinPilot 3.0 
was used to search UniProt-SwissProt with contaminants appended (2007.01.23; 254,765 
sequences) with peptide threshold of 99.9%, and fixed modifications of iTRAQ (K, N-
term), MMTS (C). Due to variable processing of gag, we subsequently normalized virus 
from different treatments and lines using cyclophilin A, a known gag interacting host 
protein64 using the iTRAQ reporter bias correction feature built into ProteinPilot.  
 
Tandem mass spectrometry (LCQ). 500 µg of capsid equivalents of DM purified HIV-
1MNCl.4 /H9virus was desalted and subjected to reverse phase HPLC analysis on a 
Beckman PF2D system as previously described into 37 fractions, digested and tandem 
MS performed as described.109 Briefly, ESI-MS/MS of tryptic peptides was performed on 
an LCQ-ion trap-MS/MS instrument using a 60 minute gradient as previously 
described.110 Data were acquired using Xcalibur 2.07 (Thermo, San Jose, CA). The three 
most intense ions (minimum signal of 100,000 ions) were selected for MS/MS 
fragmentation using a normalized collision energy of 35. Dynamic exclusion was applied 
for 30 seconds after 1 MS/MS acquisition, with a mass window of 2 Da.  
 
Comparison between MDM derived virus and T cell HIV-1. 17 raw files for the analysis 
of MDM derived virus from a study published by Chertova et al.74 were obtained from 
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the authors and analyzed in parallel with 37 DM purified fractions of HIV-1/H9. Briefly, 
peaks were selected and de-isotoped using DeconMSn for MDM derived LTQ data and 
using ReAdW (2009v) for LCQ derived HIV-1/H9. The data were then searched using 
PepArML111, which uses multiple different search algorithms (OMSSA, X!Tandem with 
native, k-score and s-score scoring, MASCOT, MyriMatch, and InSpecT) as previously 
described.112 Carbamidomethylation was set as a fixed modification and oxidized 
methionine was set as variable modification. Mass tolerances on precursor and fragment 
ions were set at 1.5, and .8 Da, respectively and missed cleavage as 1 using a specific 
search. The database used for search was the UniProt-SwissProt database (version 
2010.11.02; 522,019 sequences). Peptides were combined on PepARML using a random 
forest approach (Weka)113 and the results were then parsed into MASPECTRAS 2.0114 
with minimum 2 peptide for a protein and a spectrum false discovery rate of 5%. Peptides 
assigned to keratin were excluded, and since the analysis was focused on host proteins, 
viral peptide assignments were excluded. Protein redundancy was removed by MS based 
evidence clustering.114 The data analysis pipeline meets all MIAPE standards115 and the 
proteomics data have been deposited in the ProteomeExchange via the PRotein 
IDEntifications database (PRIDE) partner repository with the dataset identifier 
PXD000064.116  
 
HIV protein interactions and network/pathway analysis. Network and pathways analysis 
was performed using the GeneMANIA gene network tool, which contains 353 human 
interaction networks based on data from BIND, IntAct and other interaction databases, 
using association data from protein and genetic interactions, known and predicted 
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pathways, co-expression, co-localization and protein domain similarity.117 Our analysis 
was performed using only protein physical interaction data from GeneMANIA with 
GeneMANIA Cytoscape plugin. Identified host proteins were searched in the HIV-1, 
Human Protein Interaction Database for reported interactions in the literature.118-120 
 
Safety considerations. All work with infectious HIV was performed in a biosafety level 3 






DM virion preparations allows for the separation of virus from microvesicles. The DM 
purification method is based upon our previous studies using beta-cyclodextrin to 
manipulate cholesterol in HIV-1 particles.54,55 As viral purification through a 20% 
sucrose gradient results in co-purification of HIV and microvesicles of similar density, 
we differentially modified microvesicle and virion density by adding excess cholesterol 
to purified viral stocks. Cholesterol is differentially incorporated into microvesicles and 
virions, resulting in density changes that allow for the separation of highly purified 
virions from microvesicle contaminants. DM HIV-1 purity was assessed using CD45, a 
well-defined marker of vesicle contamination, resulting in a >90% reduction of material 
and elimination of microvesicles (Figure 3-1, A-C). DM HIV-1 had a <1 log infectivity 
decrease (not shown) and virion morphology was substantially altered (Figure 3-1,D).  
To rule out artifact, we validated DM purified samples with an alternative purification 
method (OptiPrep; 60% iodixanol).107 The relative abundances of proteins by quantitative 
proteomics (iTRAQ) from both samples were compared against virus pelleted through a 
20% sucrose gradient. Virus preparations were carefully normalized by capsid protein 
(p24) by ELISA, and subsequently validated by SDS-PAGE (data not shown) prior to 
digestion with trypsin and labeling with iTRAQ reagents.  
 
In an iTRAQ experiment, post-hoc corrections for the relative abundance of reporter ions 
are made to ensure that no single reporter is over-represented in the data analysis.121 This 
can occur for a multitude of reasons, including variations in manufacturing of reagents or 
sample preparation conditions during labeling. Recently Breitwieser and colleagues  
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Figure 3-1. Purification of HIV-1 virions using density modification.  
DM HIV-1 purity was assessed using CD45, a marker of vesicle contamination (Fig 1A). 
Isolated microvesicles (MV) from the H9 (Fig 1B) or Hut78 cell line (Fig 1C) were 
eliminated with this method (>90% of material was lost). HIV-1 infectivity was 








showed that iTRAQ reporter intensities are valid over one log of dynamic range.121  In 
this study, we manually adjusted iTRAQ reporter bias to ensure that no purification 
method resulted in a reporter ratio >1 when compared to the control preparation, as 
protein can only be depleted in the purification process.  
 
For comparisons between viruses (CEMx174 vs H9 derived HIV-1), we initially 
attempted to adjust iTRAQ reporter bias based upon spectra assigned to HIV-1 capsid 
protein (p24). However, p24 resulted in unreliable bias estimation secondary to the 
extreme sequence divergence of HIV capsid protein and improperly assigned viral 
peptides by ProteinPilot. Instead, we investigated the use of spectra assigned in control 
preparations to the host protein cyclophilin A (CypA). The host protein CypA has been 
reported to be included in virions,64 but has not been reported to be present in 
microvesicles except under conditions of extreme cellular stress, such as cellular 
irradiation.122,123 CypA incorporation has also been reported to be important for maximal 
HIV infectivity and it has been suggested that the absence of CypA incorporation leads to 
HIV restriction.65 HIV recruits CypA to ~10% of its capsid monomers in newly 
assembled cores and the CypA binding site on capsid is highly conserved in all primate 
lentiviruses.64,65 We therefore adjusted iTRAQ reporter bias using CypA peptides, whilst 
ensuring that the most abundant protein was normalized to a 1:1:1 ratio between different 
preparations. Indeed, this method did not violate our rule of host proteins in the 
purification groups being less than control. Final adjustments were minor and accounted 
for a 25% decrease in CypA for CEMx174 derived HIV-1 and a 35% decrease in CypA 
for H9 derived HIV-1 using DM purification. Comparatively, a 10% and 40% decrease in 
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CypA were observed using OptiPrep purification for CEMx174 and H9 derived HIV-1, 
respectively. These results suggest that CypA may indeed be present in microvesicles 
induced by HIV-1 infection, like other forms of cellular stress.  
 
For virions produced in either H9 or CEMx174 cells, we observed a decrease in protein 
abundance for both DM and OptiPrep purified virions compared to control methods. DM 
purification significantly reduced the abundance of 34 proteins for CEMx174-derived 
HIV-1 virions, whereas OptiPrep purification resulted in significant reductions of 8 
proteins (Table 3-1). Similar results were observed for H9 cells (data not shown). Many 
proteins that were reduced in quantity for either DM or OptiPrep purification have been 
shown to be in microvesicles;124-126 the greater reduction in proteins using DM 
purification suggests that this method is a more stringent purification measure than 
OptiPrep purification. However, many of the reduced proteins have also been shown to 
be incorporated into HIV virions and we cannot rule out the loss of a subset of viral 
particles in either purification method.58 
 
iTRAQ analyses can differentiate HIV-1 virions derived from a T cell line and a B cell/T 
cell hybrid cell line. Viral stocks produced from different cell lines displayed unique 
phenotypes, and virion composition reflected the progenitor cell type. DM purified viral 
stocks derived from CEMx174 and H9 cells were compared. Table 2-2 shows that 15 
proteins can be used to differentiate between the cell lines. Notably, virions produced 
from CEMx174, which is a T-cell/B-cell hybrid,127 contained higher levels of CD48 
antigen precursor, a marker of B-cell activation.128 
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Table 3-1. Reduced proteins in HIV-1 derived from CEMX174 cells following virion 














zeta/delta 6 0.5151 0.0371 0.7533 0.0613 
56.5 P63261 Actin, cytoplasmic 2 29 0.5099 0.0013 0.92 0.1083 
41 P06733 
Alpha-enolase Homo 
sapiens (Human) 9 0.5058 0.0001 0.7502 0.0038 
33.3 P07355 Annexin A2 9 0.4459 0.0015 0.8047 0.0188 
61.2 P80723 
Brain acid soluble 
protein 1 7 0.523 0.0409 0.7312 0.0264 
23.5 P09326 
CD48 antigen precursor 
(B-lymphocyte 
activation marker 
BLAST-1) 5 0.4887 0.005 0.949 0.5258 
41.5 O00299 
Chloride intracellular 
channel protein 1 5 0.5008 0.0012 1.0572 0.5918 
28 P31146 Coronin-1A 4 0.5112 0.0003 0.8208 0.011 
30.1 P68104 
Elongation factor 1-
alpha 1 8 0.5466 0.0006 0.9394 0.4253 




dehydrogenase 3 0.4113 0.0231 0.8528 0.5458 
51.2 P11142 
Heat shock cognate 71 
kDa protein 18 0.5481 0.0042 0.9216 0.5634 
29.1 P08238 
Heat shock protein HSP 
90-beta 8 0.5316 0.003 1.0241 0.8397 
46.6 P30453 
HLA class I 
histocompatibility 
antigen, A-34 alpha 
chain precursor 14 0.6886 0.0117 0.9655 0.7305 
31.1 P01903 
HLA class II 
histocompatibility 
antigen, DR alpha chain 
precursor 7 0.4474 0.007 0.9419 0.4304 
52.6 P13760 
HLA class II 
histocompatibility 
antigen, DRB1-4 beta 
chain precursor 7 0.5259 0.0458 0.9599 0.7407 
41.7 P13761 
HLA class II 
histocompatibility 
antigen, DRB1-7 beta 
chain precursor 7 0.5595 0.001 0.9605 0.6705 
25.9 P05362 
Intercellular adhesion 
molecule 1 precursor 3 0.5685 0.0489 0.8179 0.1331 





AHNAK 2 0.4589 0.0143 0.7738 0.025 
19.2 P43007 
Neutral amino acid 





32.2 Q06830 Peroxiredoxin-1 5 0.3815 0.0157 0.7814 0.0282 
23 P13796 Plastin-2 (L-plastin) 4 0.5221 0.0042 0.8782 0.1899 
16.4 Q8WUM4 
Programmed cell death 
6-interacting protein 2 0.5772 0.0397 0.8987 0.5737 
16.2 P30101 
Protein disulfide-
isomerase A3 precursor 1 0.4702 0.0423 0.7946 0.3432 
23.4 P14618 
Pyruvate kinase 




substrate 2 precursor 2 0.5057 0.0433 0.963 0.811 
24.5 P62834 
Ras-related protein 
Rap-1A precursor 1 0.4817 0.0063 0.7928 0.0465 
81.8 P62328 Thymosin beta-4 3 0.4805 0.0215 1.0323 0.7312 
31.6 P61586 
Transforming protein 
RhoA precursor 2 0.4166 0.0123 0.9393 0.5786 
37.1 P67936 
Tropomyosin alpha-4 
chain 3 0.506 0.0248 0.8225 0.3176 
17.6 Q9BQE3 Tubulin alpha-6 chain 3 0.4275 0.0074 0.8795 0.2247 
72.4 P62988 Ubiquitin 3 0.4191 0.0037 0.9396 0.5418 
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Table 3-2. Proteins able to differentiate between HIV-1 derived from CEMX174 





Number Protein Name 
Peptides 
(95%) CEM:H9 P value* 
61.2 P80723 Brain acid soluble protein 1 7 6.1243 0.042 
23.5 P09326 CD48 antigen precursor 5 1.8935 0.0377 
45.8 P23528 Cofilin-1 6 2.1352 0.0266 
29.4 P04075 Fructose-bisphosphate aldolase A 4 2.2855 0.0409 
33 P04899 
Guanine nucleotide-binding protein G(i), 
alpha-2 subunit 5 2.3068 0.0296 
46.6 P30453 MHC class I antigen A*34 14 3.3001 0.0184 
16.9 P04233 
HLA class II histocompatibility antigen 
gamma chain 2 4.2203 0.0346 
47.9 P07737 Profilin-1 4 2.4426 0.0169 
23.4 P14618 Pyruvate kinase isozymes M1/M2 5 1.8639 0.016 
26.4 Q15286 Ras-related protein Rab-35 3 2.054 0.013 
21 P05023 
Sodium/potassium-transporting ATPase 
alpha-1 chain precursor  7 2.0799 0.0344 
81.8 P62328 Thymosin beta-4 3 2.4172 0.0273 
37.1 P67936 Tropomyosin alpha-4 chain 3 2.7548 0.0016 
17.6 Q9BQE3 Tubulin alpha-6 chain  3 1.9302 0.0058 





Shotgun analysis of DM modified HIV-1 identifies 283 host proteins. While our iTRAQ 
experiments provided us with a powerful method of determining our relative purification 
efficiency, no multidimensional protein separation strategies were used for this 
experiment. Therefore, to extend our coverage of the DM HIV proteome, we performed 
HPLC separation of DM-HIV-1, and collected 37 fractions that were then subject to 
analysis by MS/MS on LCQ-duo equipped with an Agilent nano-HPLC system. The 
resulting spectra were pooled and searched on our MS-analysis pipeline. We found that 
the peptides were assigned to >1800 proteins, including redundant assignments; these 
proteins clustered to 283 individual host proteins using a spectrum false discovery rate of 
5%. 
 
MDM and T cell-derived HIV-1 virions incorporate a limited number of shared host 
proteins. To determine which host proteins were incorporated to the virion both in T- and 
in macrophage-cell types, we compared our T cell dataset to the MDM-derived HIV-1 
dataset generated by Chertova and colleagues.74 To ensure that the datasets were 
comparable, the Chertova dataset was reanalyzed using our data analysis pipeline.129 136 
(38 clustered) proteins were unique to the macrophage derived virus, and 1339 (241 
clustered) proteins were unique to the T-cell derived virus. 680 (79 clustered) proteins 
were shared between the MDM derived and T-cell derived dataset (Figure 3-2). Of the 79 
common proteins, many of these proteins were isoforms of the same protein with 
different peptides identified (Table 3-3). The majority of these proteins were distinct 





Figure 3-2. Comparison between the published MDM derived HIV-1 and other 
datasets. (A) Comparison of the published MDM-derived HIV-1 dataset by Chertova et 
al. and the dataset after reanalysis through our bioinformatics pipeline. Based on 
matching protein accession numbers, 42 proteins from the reanalysis are common to the 
published list. (B) Comparison of the published MDM-derived HIV-1 dataset by 
Chertova et al. with the T cell-derived HIV-1 dataset. The two datasets contain 35 
proteins in common. (C) Comparison between the reanalyzed MDM derived HIV-1 
dataset and the T cell-derived HIV-1 dataset. 76 clusters of proteins are in common to 











% of Sequence 
Coverage 
No. of Unique 
Peptides 
No. of Unique 
Spectra 
2',3'-cyclic-nucleotide 3'-phosphodiesterase CNP 11.17 5 7 
6-phosphogluconate dehydrogenase, decarboxylating Pgd 9.94 3 5 
Actin (37 isoforms) act1 12 827 8432 
Alpha-1-antiproteinase SERPINA1 32.22 17 38 
Alpha-2-H AHSG 25.35 9 16 
Annexin A2 ANXA2 52.22 21 62 
CD44 antigen CD44 7.28 4 14 
Cell division control protein 42 homolog CDC42 36.65 6 26 
EH domain-containing protein 4 EHD4 24.59 9 12 
Elongation factor 1-alpha (4 isoforms) eFF1a 10.9 6 78 
Ezrin EZR 18.44 9 23 
Heat shock 70 kDa protein (11 isoforms) HSPA 15.78 132 516 
Heat shock cognate 71 kDa protein HSPA8 39.63 26 126 
Heat shock protein H HSP90AB1 24.45 15 52 
Hemoglobin fetal subunit beta  - 60.69 10 101 
Hemoglobin subunit beta (3 isoforms) HBB 27.9 4 18 
HLA  A (MHC class I) HLA-C 19.13 10 39 
HLA DR (MHC class II) (3 isoforms) HLA-DRB1 21.06 5 28 
Moesin MSN 23.4 15 70 
P (Ankyrin Repeat Containing) POTEE 10.33 16 168 
Peptidyl-prolyl cis-trans isomerase A  
(cyclophilin A) PPIA 56.37 14 103 
Phosphoglycerate kinase 1 PGK1 32.86 12 22 
Pyruvate kinase isozymes M1/M2 PKM2 40.12 16 40 
Ras-related C3 botulinum toxin substrate 2 Rac2 30.73 6 7 
Syntenin-1 SDCBP 10.2 7 9 





protein EH4, a phosphodiesterase, CypA and heat shock proteins. The only conserved 
membrane proteins identified were syntenin-1 (a TEM protein) and CD44 (hyularonic 
acid receptor), a marker presently used in commercial kits to enrich HIV.  
 
As the conserved set of proteins may represent important cellular partners for the HIV 
virion, we conducted a literature search to determine whether the identified host proteins 
have been reported to be relevant in the HIV lifecycle and interact with viral proteins 
(Table 2-4). Out of the 26 protein clusters reported, 16 have previously been described in 
association with HIV-1, and 10 represent previously undefined associations. 
 
To determine if the conserved set of proteins between MDM and T-cell derived HIV-1 
could be used to reconstruct the protein composition of each virion, we seeded the 
GeneMANIA human network database with the core set of proteins and allowed for the 
1000 most-related interacting partners. We found that 29% and 53% of host proteins from 
T cell derived or MDM derived HIV-1, respectively, could be explained by primary 




Table 3-4. HIV-1-human protein interactions reported in the literature.118-120 
Host Protein HIV Protein Interaction 
2',3'-cyclic-nucleotide 
3'-phosphodiesterase 
Activated by: tat 
Actin 
Inhibited by (multiple isoforms): env 
Binds (multiple isoforms): gag, nef 
Interacts with (multiple isoforms): gag 
Associates with (multiple isoforms): nef 
rearrangement induced by (multiple isoforms): nef, tat 
Cleaves (multiple isoforms): pol 
Associates with (beta-actin): rev 
Downregulated by (multiple isoforms), upregulated by (beta actin): tat 
Polymerization enhanced by (gamma 1 propeptide): vpr 
Alpha-1-antiproteinase Interacts with: env 
Annexin A2 
Colocalizes with, interacts with (isoform 1): gag 
Downregulated by (isoform 2): tat 
CD44 Downregulates: vpr 
Cell division control 
protein 42  
Inhibited by, interacts with, upregulated by: nef 
Eukaryotic translation 
elongation factor 1 
alpha 1 
Inhibited by: gag 
Binds: gag, pol 
Interacts with: tat 
Ezrin 
Binds: env 
Interacts with: env, gag 
Incorporates: gag 
Upregulated by: vpr 
heat shock protein 
70kDa 
Interacts with (protein 5), upregulated by (multiple proteins), inhibits (multiple proteins): 
env 
Incorporated by (multiple proteins), stimulates (multiple proteins), inhibits (protein 8): gag 
Regulates (multiple proteins): tat 
Inhibits (protein 1a), binds (protein 1a), competes with (multiple proteins): vpr 
MHC Class I 
Interacts with, complexes with: env 
Binds: env, gag, nef, pol 
Upregulated by: env, tat 
Colacalizes with, inhibited by, modulated by: nef 
Downregulated by: nef, tat, vpu 
MHC Class II 
Associates with, incorporated by: env 
Upregulated by: env, tat 
Inhibited by, interacts with: env, nef 
Colocalizes with, relocalizes, relocalized by: gag 
Downregulated by: gag, nef, tat 
Moesin 
Binds, relocalized by: env 
Incorporated by: gag 
Peptidyl-prolyl cis-trans 
isomerase A  
(cyclophilin A) 
Inhibited by, required by: env 
Incorporated by, modulates, interacts with, stabilized by: gag 
Binds: gag, nef, vif 




Interacts with: nef 
Activated by, downregulated by: tat 
Syntenin-1 Upregulated by: env 
Ubiquitin Ubiquinates: gag, rev, tat 
No interactions have been reported for 6-phosphogluconate dehydrogenase, 
decarboxylating; Alpha-2-H; EH domain-containing protein 4; HSP90AB; Hemoglobin 
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fetal subunit; HBB; P (Ankyrin Repeat Containing); Phosphoglycerate kinase 1; Pyruvate 





Using a novel HIV purification assay we have found a common set of host proteins that 
are incorporated into virions produced from monocyte-derived macrophages (MDMs) 
and T cells. DM purification modifies the density of microvesicles, allowing for the 
purification of large quantities of microvesicle-free viral stocks. This method may not be 
necessary for virion purification from infected MDMs, since these cells have longer half-
lives than T cells, allowing for higher virion yields, and MDMs produce a lower level of 
contaminating microvesicles compared to lymphocytes.74,102,103 We found that DM clears 
>90% of microvesicles using CD45 as a marker protein (by densitometry, not shown). 
We compared this method to the OptiPrep (60% iodixanol) method for microvesicle-free 
HIV-1 purification.107 Results were normalized by CypA, as CypA has been reported to 
be incorporated into viruses in an approximately 1:10 ratio to gag particles.64,65 While 
using a viral protein for normalization might seem like an adequate normalization tool, 
viral protein sequence divergence and differential processing by progenitor cell type 
make it difficult to normalize by these proteins. Both OptiPrep and DM purification 
methods produce consistent results, reducing levels of proteins known to be incorporated 
in microvesicles. DM purification proved to be a more stringent approach, as there was a 
greater reduction in CypA levels coupled with a higher number of significantly reduced 
proteins compared to OptiPrep methods. Ott and colleagues developed a purification 
technique based on similar principles, in which proteins in microvesicles are digested 
with the nonspecific serine protease subtilisin.105 The subtilisin digestion decreases 
microvesicle density, allowing for purification of HIV particles by density gradients, 
allowing for >95% purification of virions.104 Subtilisin treatment digests membrane 
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proteins, though, and is only suitable for determining the composition of proteins inside 
the virion.105 
 
We cannot rule out that DM purification also modifies viral composition in some manner, 
as cholesterol has been reported to be an integral component of the viral membrane, and 
that this may account for some of the protein reduction.54,55 Notably, electron 
micrographs of DM-treated virions show some membrane irregularities, which could 
impact protein composition of the purified viral stocks. This may explain the absence of 
some host membrane proteins which have been reported to be incorporated into HIV 
virions. Of note, tetraspanin proteins were not detected in our analysis. This may not be 
surprising, though, given that tetraspanin interactions are affected by cholesterol and the 
DM assay may have disrupted TEMs.130 It is of note that very few membrane-bound 
proteins were observed in the common set of proteins, particularly given that TEMs have 
been shown to be of importance in HIV-1 biology.131-133 We did detect the PDZ-
containing protein syntenin-1 in both MDM- and T cell-derived virions. Syntenin-1 has 
been shown to have a large variety of interaction partners, including syndecan, Rab 5, 
Rab 7, CD63, and phosphoinositol lipids. Many of the partners for syntenin-1 are 
involved in membrane trafficking, including tetraspanin and TEM-associated 
proteins.134,135 Since TEM components are frequently reported in the viral envelope, but 
were not detected in this analysis, it is possible that syntenin-1 is involved in the HIV-1-
TEM interaction, and that the syntenin-1-TEM interactions were disrupted by our 
purification process. This may implicate syntenin-1 as an important mediator of viral 
envelope composition. However, preliminary data with siRNA knockdown of syntenin-1 
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in HIV-infected Jurkat cells has not demonstrated any effect on virion production (data 
not shown), so the importance of syntenin-1 in the HIV lifestyle remains speculative. 
 
The incorporation of CD44, a receptor for hyaluronic acid, also provides potential fitness 
benefits for a lentivirus. HIV replicates in activated T cells, so an attachment to 
hyaluronic acid may allow the virus to target areas of inflammation, as CD44 induction is 
a first step of immune activation and also involved in T cell trafficking.136 Notably, it has 
been reported that CD44 cell-surface expression is lost in HIV-infected monocytic cell 
lines, resulting in cell aggregation.137 
 
Using quantitative proteomic analyses on DM-purified input, we were able to 
differentiate between viral stocks prepared from the H9 T cell line and the CEMx174 B 
cell/T cell hybrid line. There were several proteins which could differentiate between the 
two stocks, including the B cell activation marker CD48 precursor, which is not 
unexpected considering the cell line origins128. These results indicate that proteomic 
analysis in combination with several purification techniques can be used to differentiate 
viral stocks from multiple sources. These methods may be applicable to identifying the 
cell source of virus produced from latently infected cells. These methods may also be 
used to differentiate between viruses from various cellular reservoirs within the host. 
 
We further compared DM purified viral stocks from H9 cells to a published database of 
MDM-derived viral stocks. To increase the validity of this comparison, raw data from the 
Chertova study collected using similar MS instrumentation employed in the current study 
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was reanalyzed using the bioinformatics pipeline developed by our group. This method 
ensured that both datasets were analyzed using the same stringent search criteria. Using 
this comparison, we identified a common set of 26 proteins that are incorporated into 
HIV virions produced in both MDM and T-cell lines. As these proteins are incorporated 
in virions produced in both cell types, we hypothesize that these proteins may have direct 
interactions with viral proteins or may be important in the viral life cycle. 
 
The base host protein composition in virions is mainly actin, chaperones, CypA and a 
handful of other proteins. Many of these have been shown to have functional impact on 
the HIV lifecycle. The importance of CypA on the viral life cycle has been well 
documented.138 CypA is believed to regulate the capsid interaction with host factors, 
either during uncoating or during other lifecycle processes.139 The protease α1-antitrypsin 
(SERPINA1; AAT) blocks protease cleavage of gp160 and gag polyprotein. Thus, it is 
not surprising that HIV protease binds and cleaves AAT, and this binding may account 
for the incorporation of AAT in HIV particles.140-142 Our results suggest that HIV-1 
virions have evolved to target a pathway enriched in ERM family proteins and vesicle 
trafficking, based on the conserved incorporation of EHD4 in T cell and MDM derived 
virions. EHD4 has been shown to regulate transport from the early endosome to the 
recycling endosome and the late endocytic pathway.143,144 EH domains bind Rab proteins, 
which are known to interact with the HIV protein rev.145 A recent study has suggested a 
role of HSP90AB in HIV replication. Inhibition of HSP90AB resulted in anti-HIV 
activity in vitro, with ritonavir-resistant viruses showing hypersensitivity to the 
inhibitor.146 Another agent with anti-HIV activity was found to bind HSP90AB and 
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prevent dimerization.147 Annexin A2, a protein involved in membrane trafficking, likely 
bridges the gap between the cytoskeletal proteins and the viral membrane. Annexin A2 
binds HIV gag and siRNA knockdown of the protein can reduce infectivity of virions 
generated in MDMs, but this may be cell type dependent.148-150  
 
Other identified proteins, including cytoskeletal and HLA proteins have repeatedly been 
reported in the literature as interacting with HIV proteins.69,74,105,151 Further, many of the 
proteins identified in this study, including actin, 2',3'-cyclic-nucleotide 3'-
phosphodiesterase, CypA, EEF1A-1, ezrin, annexin 2, HSP70, and HSC71, have also 
been identified in a quantitative proteomic analysis of an HIV-1 lentivirus vector 
produced in 293T cells.152 Thus, this common set of proteins identified in this study is 
recapitulated by findings by other groups. 
 
Given the large number of host proteins incorporated into the virus and the limited 
number of viral proteins, it is plausible that only a few specific interactions between virus 
and host proteins allows it to package a large array of host proteins. Host proteins that 
have a direct interaction with HIV proteins would serve as protein hubs. The 26 proteins 
identified to be common to the two different cell types are predicted to interact with 
>1000 related human proteins. Many of these secondary interacting proteins are 
commonly reported to be incorporated into virions, including ERM proteins and adhesion 
molecules. By assigning query based network weights (GeneMANIA, see methods), 
these associational proteins are predicted to interact with 62% and 38% of the proteins 
common to T cell and MDM derived HIV-1 respectively. However, it is important to note 
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that many more T-cell derived proteins were identified than MDM HIV-1 derived 
proteins, so this may skew this analysis. Additionally, protein prediction network 
algorithms are based on protein-protein interactions; other interactions (e.g., lipid or 
nucleic acid mediated) are not modeled. Thus, only a few direct interactions within the 
virus may dictate the host protein composition in nearly limitless dimensions. Ultimately, 
the host protein composition, as well as interaction differences between cell types, may 
drive virion phenotypic diversity, despite conserved viral protein-host protein interactions 
between cell types (Figure 3-3). While we do not intend to minimize the functional 
importance of other host proteins incorporated into HIV-1 outside of this minimal set of 
proteins, it is likely that therapeutic strategies targeting proteins other than these core 
proteins would result in limited efficacy due to the high degree of plasticity apparent with 
HIV. Therefore, we would propose that therapeutic or drug development efforts targeting 
host-virus interactions be focused on interacting proteins showing direct interaction with 
HIV proteins that are conserved between T cells and macrophages.  
 
Finally, this study demonstrates the critical nature of harmonized data analysis when 
making inter-study protein comparisons. Existing studies have demonstrated the lab-to-
lab and instrument-to-instrument variability in proteomics studies of identical samples, as 
well as search results from different search algorithms.153,154 Our re-analysis of the 
historical data from Chertova et al using current FDR-driven statistical analysis resulted 
in a truncated list of virally incorporated host proteins, comparable to what we observed 
experimentally in our work. This demonstrates the need for archiving of instrument raw 
data files so they may be subject to reinterpretation as bioinformatics improvements are  
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Figure 3-3. Hypothetical schematic of the impact of primary HIV-host protein 
interactions on virion phenotype.  
HIV proteins interact with a common set of host proteins that is found in multiple cell 
types capable of sustaining HIV infection. These common set proteins have secondary 
and tertiary interactions with both cell-specific and common protein partners and these 
interactions determine the phenotype of released virions. Thus, despite a limited number 
of HIV-host protein interactions, viral diversity is driven by the secondary and higher 







developed, and highlights the danger of making protein comparisons from tables in the 
published literature, particularly with regard older data that was not filtered by FDR or 
another stringent statistical measure. 
 
Using a proteomic analysis approach, this study identifies proteins that are incorporated 
into the virus in multiple cell types, and many of these proteins have been shown to be 
relevant to the HIV life cycle. These proteins may represent important conserved 








THE ROLE OF TETRASPANIN PROTEINS IN HOST PROTEIN 






Tetraspanin family proteins are four-pass membrane proteins that are highly conserved 
across vertebrate organisms. Tetraspanin proteins have a small extracellular loop (SEL; 
13-30 amino acids), large extracellular loop (LEL; 70-140 amino acids), short 
intracellular loop, and C- and N-terminal tails.155 There are 33 known human tetraspanin 
proteins, with tetraspanin proteins found in virtually all cell types.156 Experimental data 
have shown tetraspanin family members to be involved in cell fusion,157,158 adhesion,159-
166 cell spreading,167 proliferation, signaling,168-170 intracellular vesicle trafficking,171-173 
bacterial and viral lifecycle,174-184 immune response,169,185-190 vascular morphogenesis and 
remodeling,159,160,162,191 tumor progression and metastasis,192,193 neurite navigation, 
thrombosis, and apoptosis.194 Due to the large number and diversity of functions, 
tetraspanins have been hypothesized to ultimately function as membrane organizers. 
[reviewed by Martin Hemler195,196] 
 
As tetraspanins have been reported to be important in many different cellular functions, 
they must be capable of directly or indirectly interacting with a large number of proteins, 
including cytoskeletal proteins, adhesion molecules, proteins involved in the immune 
response, and many other proteins with varying functions.197,198 Many of these 
interactions have been shown to be mediated through the LEL.161,169 Tetraspanins and 
their interacting proteins form what is often called tetraspanin enriched microdomains 
(TEMs). TEMs can be viewed as a clustered microdomain, in which tetraspanins and 
their partners fluidly interact with frequent contact exchanges, as illustrated in Figure 4-1 
[reproduced from Charrin 2009].199 This is supported by single molecule interaction  
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Figure 4-1. A dynamic view of the tetraspanin web.199  
This model is based on biochemical analysis of the tetraspanin web and the recent 
analysis of the dynamic of CD9 and CD151. For clarity, two tetraspanin/partner pairs are 
labeled in red and blue, and the traces correspond to their movement. Left: basal level of 
interactions: small clusters of tetraspanins (T1, T2, . . . ), each specifically associated with 
a molecular partner (P1, P2, . . . ), would patrol in the plasma membrane, frequently 
interacting with other clusters and exchanging some of their constituents, contributing to 
the diversity of interactions within the tetraspanin web. Right: upon particular 
stimulations, which remain largely to be defined, some tetraspanins become confined 
within discrete areas of the plasma membrane where more stable interactions take place. 
The model shown here is based on the transfer of one tetraspanin to the tetraspanin-
enriched areas, but other models such as the gathering of several clusters are possible.199 
[This research was originally published in Biochemical Journal. Charrin S, le Naour F, 
Silvie O, Milhiet PE, Boucheix C, Rubinstein E. Lateral organization of membrane 







studies indicating that diffusional trapping through protein-protein interactions 
concentrate or exclude proteins from lipid ordered domains.200 Thus, TEMs are believed 
to be dynamic microdomains that are enriched in specific proteins, although the protein 
composition of TEMs will likely vary depending on cell type and cell status. In this 
model, there is likely to be temporal variance in a single TEM as well.  
 
In addition to being enriched in specific proteins, TEMs are also enriched in specific 
lipids, including sphingomyelin, glycosphingolipids and cholesterol.201 Notably, the lipid 
composition of TEMs is similar to that of “lipid rafts” and, therefore, TEMs can be 
viewed as lipid ordered domains.197,198 This has implications for HIV biology, as HIV has 
been shown to bud from lipid ordered domains. Further, many tetraspanins are localized 
to late endosomes/multivesicular bodies (MVBs).125,202-214 This is also the site of HIV 
assembly in macrophages.213,215 It is, therefore, not surprising that tetraspanins are 
frequently reported to be incorporated in the viral envelope.74 Indeed, several studies 
have shown that TEMs serve as the budding site for HIV in macrophages and CD4+ T 
cells.215-217 Data also indicate that tetraspanins and associated proteins are important in 
HIV envelope fusion, with one group indicating that tetraspanins are required for 
productive HIV infection in macrophages.218-220 Others have shown that the extracellular 
domain of CD63 can inhibit HIV infection in macrophages.221 Additionally, CD81 
downregulation or blocking by antibody in MOLT cells decreased HIV release.133 
Surface CD81 expression is decreased in CD4+ T cells in HIV-infected persons, 
compared to healthy controls; however CD81 mRNA increases in these subjects, 
suggesting post-translational changes in CD81 protein.222 As CD81 is incorporated into 
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HIV virions, it is conceivable that CD81 decreases on the surface of CD4+ T cells is due 
to viral budding. 
 
It should also not be surprising that many of the proteins reported to be found in TEMs 
are also incorporated into the HIV envelope and that the HIV envelope is similar in lipid 
composition to TEMs. Based on these similarities, it is possible that tetraspanins serve as 
a primary determinant of host protein incorporation in HIV virions and, by extension, as 









Materials and Methods 
Cell culture. All cells were propagated in RPMI supplemented with 10% FBS (HyClone), 
100 μg/ml streptomycin, and 100 U/ml penicillin. 
 
Flow Cytometry. Flow cytometry was performed by first fixing cells with phosphate-
buffered saline (PBS) containing 2% paraformaldehyde and then permeabilizing cells 
with PBS buffer containing 1% BSA, 5% normal goat serum (NGS), and 0.2% saponin, 
followed by staining with appropriate antibodies (Abs). Infection of cells was determined 
by flow cytometry using fluorescein isothiocyanate (FITC)-conjugated anti-p24 
(Coulter). The primary MAbs were detected with Alexa Fluor 647-conjugated goat anti-
mouse polyclonal antibody. Virus production was measured by anti-p24gag enzyme-
linked immunosorbent assay (ELISA). Compensation was performed with single-stained 
cells. Data were collected on FACSCalibur (BD Biosciences) instruments and analyzed 
with FACSDiva (BD Biosciences) or Flowjo (Tree Star) software. For 
immunofluorescence staining, cells were fixed with 2% paraformaldehyde in PBS and 
permeabilized with PBS containing 5% NGS, 1% BSA, and 0.25% Triton X-100. Cells 
were than stained with indicated primary and secondary Abs. 
 
Transfections. Transient transfections were performed using Lipofectamine 2000 
(Invitrogen). The siRNAs were nucleofected into CD4+ T cells using an AMAXA 




Infectivity Assays. LuSIV cells (2 × 104 cells/well) were seeded into 96-well. Cells were 
then disrupted with passive lysis buffer (Promega), and luciferase activity was measured 
using a reporter assay kit (Promega) 36 h after transfection. Transfections were 
performed in triplicate, and results were normalized to the Renilla luciferase signal. Each 
experiment was performed at least three times. 
 
Western blots. Cells were washed with ice-cold PBS and then lysed on ice for 30 minutes 
with buffer containing 150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% SDS, 50 mM 
Tris-HCl (pH 7.5), and protease inhibitors (Roche). Protein lysates were clarified by 
centrifugation at 15,200 × g at 4°C for 20 minutes. Protein lysates were fractionated by 
SDS-PAGE, transferred to nitrocellulose, and detected by immunoblotting with an 
primary MAb at a 1:1,000 dilution. Immunoreactive proteins were detected using 
horseradish peroxidase-conjugated goat anti-mouse or goat anti-rabbit IgG and an ECL 
assay (Amersham). 
 
Virus purification and infection. Culture supernatants from chronically infected cell lines 
were collected 48 hours after transfection, centrifuged at 1,000 × g to remove cell debris, 
filtered through a 0.45-μm-pore-size filter, and concentrated by ultracentrifugation at 
100,000 × g through a cushion of 20% sucrose in PBS. The pelleted virus was 
resuspended in RPMI with 10% FBS, aliquoted, and stored at −80°C. The viral titer was 
measured by anti-p24gag ELISA. Forty-eight hours after nucleofection with siRNA, 
CD4+ T cells were infected with virus (200 ng of p24 per 5 × 105 cells) by spinoculation 
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(1,200 × g, 2 h), followed by a 2-h incubation at 37°C, and were washed three times to 
remove input virus. 
 
Differential lysis of chronically-infected cell lines and immunoprecipitation. Cells (2x107 
cells/mL) were lysed in detergent (Brij97 with metal ions or triton-x) for 40 minutes on 
ice. Lysates were spun at 15,000 RPM for 20 minutes at 4ºC and the supernatant was 
reserved. Total protein in the supernatant was quantified by BCA assay. Lysate was pre-
cleared with 10 uL protein A/G beads per 300ug protein, rotating 1 hr at 4ºC and then 
spun at 3,000 x g for 3 minutes at 4ºC. Supernatant was reserved. Lysate was adjusted to 
1 mg/mL in appropriate buffer with protease inhibitors. Per sample, 1.5 ug primary 
antibody was incubated with 300 uL lysate on ice for 2 hours. Protein A/G beads (10 
uL/sample) were added and the samples were rotated for 1 hr at 4ºC. Samples were spun 
at 3,000 x g for 3 minutes at 4ºC and the beads were reserved. Beads were washed three 
times in appropriate buffer. Remaining supernatant was removed using a 26½ guage 
needle. Beads were frozen for subsequent western blot analysis. 
 
For immunoprecipitation, 50 µL 1X loading dye was added to each sample and samples 
were boiled (100ºC) for 5 minutes. Samples were quickly spun at 15,000 RPM and 20 µL 
sample was loaded on 10% Bis/Tris NuPage gels. For control, 20 µL cell lysates and 15 
µL MN lysate (RIPA buffer) were used. For each sample 10 ug-70ug total protein was 
loaded per lane. Standard western blot procedures were followed, and blots were probed 




DR63 cell line generation. Jurkat cells (2 x 107) were suspended in 50 mL of medium 
containing 200 µg/mL ethyl methanesulfonate (Sigma) for 24 hours. Cells were washed 4 
times in a medium containing 5% FBS and then cultured in complete medium for 7 days. 
Cells expressing reduced surface CD63levels were selected for through serial negative 
selection with anti-CD63 beads. Following six passages, cells were subcloned with 
limiting dilutions in 96-well plates (1-3 cells/well). When cell densities were at 1 x 105 or 
higher, cells were assessed for surface and intracellular CD63 levels using a plate-based 





As other groups have reported that the HIV lifecycle can be impacted by tetraspanin 
proteins, we attempted to determine whether these results were reproducible. We used 
siRNA medicated knockdown of tetraspanin or the tetraspanin-associted protein 
syntenin-1 to investigate viral release. As shown in Figure 4-2, we could achieve up to 
approximately 75% reduction in tetraspanin proteins by siRNA knockdown in chronically 
HIVJRCSF-infected Jurkat cells. Additionally, we could simultaneously knockdown CD63 
and CD82 expression. Knockdown of individual tetraspanins did not affect gag levels as 
determined by intracellular flow cytometry; however CD63/CD82 knockdown did 
decrease intracellular gag expression. As shown in Figures 4-3 and 4-4, siRNA 
knockdown of neither tetraspanins nor syntenin-1 impacted viral release. 
 
We then assessed the phenotype of virions produced in these cells, hypothesizing that 
loss of reduction of tetrapsnin proteins had the potential to impact host protein 
incorporation into the viral envelope. Therefore, we assessed common integrin members 
of TEMs. While we could reduce or eliminate tetraspanin protein incorporation into the 
viral envelope, there were no observed changes in the incorporation of beta-1, beta-2 or 
alpha-5 integrins (Figure 4-5 and Figure 4-6). 
 
As the incorporation of only three integrins were used to determine whether host protein 
incorporation had been altered due to tetraspanin siRNA, we assessed the overall function 
of the virions produced in these siRNA treated cells. Infectivity of virions produced in  
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Figure 4-2. Phenotype of Jurkat/HIVJRCSF cells following tetraspanins iRNA 
knockdown. 
Jurkat/HIVJRCSF were nucleofected with siRNA against CD62, CD82, syntenin-1, an 
irrelevant control protein, or CD63 and CD82. Cellular expression of tetraspanin proteins 
(CD9, CD81, CD63, or CD82) and viral proteins (gag, p24) were assessed by flow 










Figure 4-3. Tetraspanin iRNA effect on p24 release in Jurkat/HIVJRCSF cells. 
Supernatant was collected from Jurkat/HIVJRCSF cells which had been nucleofected with 
siRNAs against CD63, CD82, CD63/CD82, syntenin-1, or an irrelevant control protein. 
Total p24 was assessed in the supernatant and then adjusted for input cell number. Cell 






Figure 4-4. Tetraspanin iRNA effect on p24 release in PM1/HIVIIIB cells. 
Supernatant was collected from PM1/HIVIIIB cells which had been nucleofected with 
siRNAs against CD63, CD82, CD63/CD82, or an irrelevant control protein. Total p24 






Figure 4-5. Effect of tetraspanin iRNA knockdown in Jurkat/HIVJRCSF on HIV 
phenotype. 
Purified viral particles collected from Jurkat/HIVJRCSF cells nucleofected with siRNA 
against CD63, CD82, CD63/CD82, or an irrelevant protein were immunoprecipitated 
with antibodies against common TEM-associated proteins. Viral phenotype was assessed 









Figure 4-6. Effect of tetraspanin iRNA knockdown in PM1/HIVIIIB on HIV 
phenotype. 
Purified viral particles collected from PM1/HIVIIIB cells nucleofected with siRNA against 
CD63, CD82, CD63/CD82, or an irrelevant protein were immunoprecipitated with 
antibodies against common TEM-associated proteins. Viral phenotype was assessed by 







these iRNA treated cells was assessed. These viral stocks showed no difference to control 
viral stocks in terms of infectivity (Figure 4-7). 
 
We also assessed the impact of blocking tetraspanins either on target cells or on virions, 
using monoclonal antibodies alone or in combination to pre-treat the target cells or 
virions. We found no effect on infectivity when pre-treating cells with mAbs to HIV 
(data not shown). We also saw no effect on infectivity when pre-treating virions with 
anti-tetraspanin mAbs (data not shown).  
 
The lack of change in TEM associated proteins in the viral envelop and in the infectivity 
of these virions was unexpected, but we hypothesized that either functional overlap 
between the tetraspanins or the transient nature of siRNA knockdown could have 
impacted these results. Therefore, we created a cell line that had significantly reduced 
CD63 levels, with the intent of using this cell line in conjunction with siRNA or shRNA 
to knock down multiple tetraspanins and assess the impact on the viral lifecycle. 
 
To create the CD63 downregulated cell line, cells were mutagenized with ethyl 
methanesulfonate (see Materials and Methods). Following mutagenesis, cells were 
serially passaged with negative selection for adhesion to anti-CD63 coated plates (Figure 
4-8). After six passages, 75% of cells did not stably adhere to the plates. These cells were 




Figure 4-7. Infectivity of HIVJRCSF produced in iRNA treated cells. 
The infectivity of viral particles produced from Jurkat cells nucleofected with siRNA 
against CD63, CD82, CD63/CD82, or an irrelevant protein was assessed through Lu-SIV 









Figure 4-8. Selection against CD63 expression in mutagenized Jurkat cells.  
Expression of CD63 in Jurkat cells mutagenized with EMS was selected against through 
sequential CD63 depletion in 96-well plates coated with anti-CD63 antibody. Enrichment 
of cells with putative depletion of cell surface CD63 was determined by the percentage of 
input cell number through the assay. Following the last depletion step, cells were 









Subcloned cells were assayed for adhesion to anti-CD63 coated plates (Figure 4-9). 
Several clones that showed reduced adhesion compared to Jurkat controls were selected 
for further analysis. These clones were expanded and tested for CD63 expression by flow 
cytometry (Figure 4-10). Clone I5 was selected based on decrease extracellular and 
intracellular CD63 expression and reduced adhesion. This clone was renamed DR63 (for 
downregulated CD63). 
 
As shown by fluorescent microscopy, DR63 cells showed reduced intracellular and 
intracellular CD63. While control Jurkat cells show CD63 in punctate clusters 
intracellularly, consistent with CD63 expression in intracellular vesicles, DR63 cells 
showed little to no CD63 in punctate clusters (Figure 4-11). Light microscopy showed 
that DR63s clustered and fused (Figure 4-12). Of interest, cells in which the CD63 
partner syntenin-1 has been downregulated show a similar pattern of clustering and 
fusion.223 
 
DR63 cells were infected with HIVJRCSF, as described in the methods. Following 
infection, cells were washed and assessed for virus release. We observed no difference in 





Figure 4-9. Subcloning of mutagenized Jurkat cells enriched for low cell surface 
CD63. 
Mutagenized Jurkat cells that had been enriched for low CD63 cell surface levels were 
subcloned by limiting dilution. Subclones were assessed for cell surface CD63 by 
adhesion assay, using a standard colorometric readout (HRP/TMB) compared to 
unmutagenized Jurkat controls. Subclones were selected based on decreased intensity 
compared to control. Clones C3, C4, D3, F3, F4, F5, G4, G5, I5, K4, L2 and L3 were 









Figure 4-10. Subclone analysis of surface and intracellular CD63 expression levels. 
Subclones of interest were phenotyped for CD63 using flow cytometry. Surface CD63 
levels were assessed in non-permeablized cells, while intracellular CD63 levels were 
assessed in permeablized cells. Flow cytometry results were compared with results from 
prior adhesion assays for the subclones. Clone I5 was selected for further analysis based 
on low cell surface and intracellular CD63 levels compared to unmutagenized Jurkat 









Figure 4-11. Fluorescent microscopy of DR63 cells. 
Fluorescent microscopy assessed CD63-FITC stained (A) permeabilized unmutagenized 
Jurkat cells and (B) permeabilized DR63 cells. Normal Jurkat cells show both surface 
CD63, as well as CD63 in intracellular vesicles (presumably late endosomes). 
Comparatively, DR63 cells show significantly lower levels of surface CD63, as well as 









Figure 4-12. Light microscopy of DR63 cells. 










Figure 4-13. HIVJRCSF release from HIV-infected Jurkat and DR63 cells. 
Jurkat and DR63 cells were infected with HIVJRCSF by spinoculation, as descried in the 











Here, we found that disruption of tetraspanin expression by multiple methods in multiple 
cell types did not significantly affect virion infectivity, production, or incorporation of 
TEM resident proteins. This was unexpected, considering the reported importance of 
TEMs in HIV biology. However, the tetraspanin class of proteins has a considerable 
amount of structural and functional overlap and it is conceivable that we simply failed to 
target a sufficient number of TEM components to disrupt the viral lifecycle. 
 
We had hypothesized that interactions between tetraspanins and adaptor proteins could 
drive host protein incorporation in the viral envelope (Figure 4-14). HIV env and gag 
have been shown to interact with the AP-2 complex during HIV assembly.224 Adaptor 
proteins have also been shown to interact with tyrosine-based (Y-X-X-φ) motif.225 
Multiple tetraspanins include this motif on their c-terminal intracellular tails, suggesting 
that the tetraspanin proteins interact with adaptor proteins. CD63 has been shown to 
interact with the µ4, µ2, µ3a and µ3b subunits of AP-3; this interaction targets CD63 to 
the late endosomes/lysosomes.226 Notably, this system bypasses the early endosomes.226 
AP-3 has also been found to interact with the HIV-1 matrix protein in a yeast two-hybrid 
system, but this interaction was not confirmed using nuclear magnetic resonance.227,228 
Hypothetically, this adaptor protein-tetraspanin interaction could serve as the bridge 
between viral proteins and the tetraspanin web. Indeed, it has been postulated by others 





Figure 4-14. A hypothetical mechanism for the incorporation of TEM-associated 
proteins into HIV-1 particles. 
In this hypothesis, TEM-resident proteins are incorporated into the viral envelope via 
interaction with tetraspanin proteins. Tetraspanin proteins interact with adapter protein 
complexes via a tyrosine-based motif in the C-terminus. Adapter protein complexes are 
proposed to interact directly with viral proteins, as well as indirect interactions. Protein 









There are several ways in which HIV may be targeted to TEMs. A number of HIV 
proteins have been reported to directly interact with cytoskeletal proteins and ERM 
proteins have been reported to be incorporated into the virus as well. The CD9 and CD81 
interacting partners EWI-2 and EWI-F have been reported to interact with ERM 
proteins.230 For HTLV-1, Mazurov and colleagues reported that the matrix domain of the 
gag protein concentrates at TEMs, interacting with CD82 and CD81.178,179 This 
interaction is  dependent on the conserved amino acids on the short CD82 intracellular 
loop or the conserved cysteines flanking the loop.178 They also determined that the matrix 
domain interacts with CD81 inner loop. To determine if there is an interaction between 
tetraspanins and HIV, tetraspanins were immunoprecipitated from infected cells. The 
immunoiprecipitant was then probed for all HIV proteins using royal human anti-HIV 
antibody via western blot, as described in the Materials and Methods. These blots were 
striped and re-probed using a monoclonal antibody against HIV p17 (matrix). For HIV, 
we found no evidence of direct interaction between p17 and CD9, CD83, CD81 or CD82 
(data not shown). 
 
The C-terminal tail of CD63 has also been shown to interact with syntenin-1, through the 
syntenin-1 PDZ domain.232 We have shown that syntenin-1 is incorporated in viral 
particles produced in both T cell and MDM cells. When treating chronically infected 
producer cells with a syntenin-1 siRNA, we found a small decrease in viral release 
compared to control and a decrease in cellular CD63. Syntenin-1 may represent a 
potential TEM access point for HIV, although no direct interaction between the molecule 
and viral proteins have been discovered. However, syntenin-1 has also been shown to 
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interact with ALIX and be of importance in exosome formation, so it may be possible 
that its inclusion in the viral particle merely represents HIV entry into the exosome 
biogenesis pathway.233 It is interesting to note that syntenin-1 plays a role in cell-cell 
adhesion in epithelial cells and knockdown of syntenin-1 has been shown to result in cell 
aggregation.223 In the DR63 cell line, we also observed cell clumping, as well as cell 
fusion. This has potential implications for HIV particles, which are required to fuse with 
plasma membranes during the viral lifecycle. 
 
One group interested in customizing retroviral-like particles for the purpose of drug 
delivery produced viral like particles (VLPs) in cells containing shRNA against CD81. 
The cells, which had 99% reduction in CD81 levels, produced VLPs that were CD81 
deficient. The group did not investigate the effects of CD81 knockdown on the 
incorporation of other host proteins in the VLPs; however, it appears that knocking down 
CD81 in this cell line (293 derivatives) did not negatively affect VLP release.234 
Similarly, we did not detect any significant differences in viral release, infectivity, or 
phenotype in these studies when knocking down CD63 or CD82. However, given the 
multiple studies from multiple groups reporting the importance of tetraspanins and TEMs 
in the HIV lifecycle, we believe that the lack of effect shown here may be due in part to 
functional redundancy within the tetraspanin class. Further, if this class of proteins and 
their associated cellular partners are of vital importance in the HIV lifecycle, HIV may 
have developed multiple access points targeting TEMs, as described in “Chapter V: 








HYPOTHETICAL DETERMINANTS OF THE  




There are a few basic requirements that drive viral evolution and, consequently, viral 
phenotype. First, the virus must be able to escape host restriction factors. For HIV, the 
accessory proteins vif and vpu (and possibly others) serve this function. These proteins 
bind ABOBEC3G and tetherin, respectively, allowing for productive viral infection.5,6 
Thus, some primary interactions between viral proteins and host proteins have been 
selected for based on host restriction pressure. In our studies, we found that HIV 
produced in T cells and macrophages incorporate the protein α1-antitrypsin (AAT), 
which blocks the cleavage of gp160 and the gag polyprotein. It has been shown that the 
HIV protease binds and cleaves AAT.140-142 Thus, AAT incorporation into the viral 
particle likely results from selective host pressure and AAT may represent a host 
restriction factor.  
 
For enveloped viruses, there is also the requirement that viral particles be capable of 
membrane fission and fusion. Microvesicles (e.g., exosomes) and HIV particles appear to 
have similar host protein and lipid compositions.58,152,235,236 These small particles tend to 
be enriched for in sphingolipids, cholesterol, tetraspanins, syntenin-1, and other proteins 
described in detail above. Further, these particles utilize similar host processes for 
generation.233,237 These common factors may reflect a need for both certain structural 
features, such as a membrane that can accommodate a greater curvature than is found in 
the cell membrane, as well as functional ability, including the potential to fuse with other 
membranes. Indeed, there cannot be unlimited methods of fission and fusion of lipid 
bilayers and there are likely specific biophysical requirements to accommodate the 
thermodynamic requirements necessary for these processes. Therefore, it should not be 
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surprising that HIV co-opts the normal cellular fission and fusion processes and the lipids 
and proteins involved are thus of vital importance in the viral lifecycle.  
 
It follows that the host protein composition of the viral particle would reflect these 
processes and that the viral envelope would mirror that of microvesicles or exosomes. As 
it is well established that HIV buds from lipid ordered domains, particularly lipid rafts 
and TEMs, we find many of the host proteins characterized in these cellular domains in 
the viral envelope. It is important to recognize that the virus “taps in” to these domains, 
and that this is likely the result of a few primary viral interactions. The literature has 
shown that HIV can interact with literally hundreds of proteins; in reality, many of these 
are most likely not primary interactions. The HIV genome only encodes for 16 proteins 
and these proteins can only make a finite number of primary interactions. Biochemical 
analyses are prone to produce artifacts indicating primary interactions when no 
interaction may occur. For example, a yeast two-hybrid system was used to show a 
primary interaction between AP-3 and gag;227 further analysis by NMR could not 
reproduce this result.228 What is notable about this example is that the original paper, 
published in the highly respected journal Cell, seemed to have strong evidence for the 
interaction, but the same group could not find this interaction using alternate methods. 
Similarly, many of the interactions reported to occur (or not to occur) may be a result of 
assay artifact or experimental conditions. Identification of true primary interactions is 
particularly important as a result, as these interactions not only arise due to selective 




In an effort to characterize these interactions that may be of importance in the HIV-1 
lifecycle, we identified host proteins in virions produced in both CD4+ T cell lines and 
MDMs. We hypothesized that incorporated host proteins of importance would not be 
dependent of producer cell type, although there certainly could be instances where 
important host proteins are cell type dependent. In our model, the common set of proteins 
incorporated into HIV-1 particles regardless of producer cell type serve as protein hubs, 
determining the viral phenotype through their primary and higher order interactions with 
other cellular proteins. This would not only drive differences in virion phenotype 
between cell types (as the host-host protein interactions will vary by cell type), but it 
would also likely drive differences in virion phenotype produced in the same cell types, 
and even from the same producer cell. Spatial and temporal differences in protein 
interactions would produce a heterogeneous viral phenotype regardless of budding 
circumstances. Consequently, this may account for the large number of incorporated 
proteins reported to be incorporated into HIV-1 particles. 
 
It remains speculative, but the inclusion of specific host proteins may result from the 
need to include lipids that are capable of fission and fusion. In the case of membrane 
fission (budding), it has been shown that membrane-associated proteins can induce 
bilayer deformation, which may result in protein aggregation.238 Specific lipids or 
cholesterol in small clusters can themselves behave effectively as membrane 
inclusions.238 By selecting proteins that have a favorable geometric mismatch—that is, 
membrane proteins that cause a curvature in lipid bilayer—HIV particles may be able to 
induce membrane deformations that are essential for the budding process. Thus, HIV may 
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use established host protein-protein networks (i.e., TEMs) to control membrane 
deformations. The identified protein syntinin-1 interacts with the protein ALIX and is a 
core component of exosome biogenesis.233 HIV-1 incorporation of syntenin-1 in both T 
cells and MDMs supports the suggestion that HIV targets the exosome biogenesis 
machinery during viral egress, regardless of cell type. It is interesting that syntenin-1 
appears to have a late-domain-like motif (the N-terminal domain of syntenin contains 
three LYPX(n)L motifs) similar to HIV p6 and EIAV p9.237,239 Syntenin-1 is also a 
known component of TEMs and it interacts with the PDZ domain of CD63 and may be 
involved in CD63 trafficking between internal membranes and the plasma membrane.232 
Given the importance of syntenin-1 in exosome formation and interaction with the 
ESCRT machinery, as well as its primary interaction with CD63 (as shown by NMR), it 
is likely that the molecule is of importance in both HIV release, as well as in determining 
the viral phenotype. 
 
HIV particles must also be able to fuse with target cells. In the hemifusion (stalk) model 
of lipid membrane fusion, the stalk must be metastable in order to allow for fast fusion, 
otherwise fusion is either extremely slow or impossible.240 Accordingly, the variation 
allowed in the membrane lipid architecture that would allow for a metastable stalk is 
small. To achieve membrane fusion, lipid bilayers could be composed of lipids with 
small spontaneous curvatures, or lamellar formers, and those with larger negative 
spontaneous curvatures, or nonlamellar formers. The ratio of these different kinds of 
lipids must be tightly regulated, as is observed for Escherichia coli and Acholeplasma 
laidlawii.240-242 HIV must also tightly control its lipid composition to retain a lipid 
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composition that remains capable of fusion with target cells. Our group has previously 
shown that cholesterol in the viral envelop is necessary for viral fusion.54  
 
HIV must also target membrane regions of cells that contain regions amenable to 
membrane fusion. The HIV fusion protein gp41 cholesterol binding is attributed to a 
cholesterol recognition consensus (CRAC) motif, which mediates gp41 binding to a 
cholesterol affinity column.243 Based on thermodynamics and steric properties, the 
transmembrane regions of certain proteins may more readily accommodate association 
with small, planar lipids. Notably, TEMs, which have four transmembrane regions, are 
enriched in lipids with these qualities. Additionally, HIV coreceptors are seven-pass 
transmembrane proteins located in lipid ordered domains, which appears to be a 
requirement for HIV fusion with target cells.244-246 It has been proposed that localization 
of coreceptors in lipid ordered domains is needed for signaling events to establish 
productive infection of a cell.247 However, it also seems reasonable that localization of 
these proteins in lipid ordered domains is necessitated by the thermodynamic 
requirements of membrane fusion. Of note, other enveloped viruses also target multipass 
transmembrane proteins during viral entry. Many other viral species also require 
cholesterol for fusion and have receptors located within lipid ordered domains (Table 5-
1). Thus, the membrane fission and fusion requirements are linked—at egress, viral 
particles must have a lipid and protein composition that allows for later fusion. They 
must then target lipid ordered regions for fusion. These requirements would be similar for 
any viral species with an envelope and would, therefore, constitute a selective pressure on 
all enveloped viruses. Accordingly, it may not be surprising that some of the host proteins  
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Table 5-1. Receptor Characteristics for Selected Enveloped Viruses. 
Virus Receptor or Coreceptor Found in Lipid-
ordered Domains 
Viral fusion requires 
cholesterol? 
CMV248,249 α2β1; α6β1; α5β3 Y Y 
EBV250,251 CD21; CD35; HLA II Y Y 
HBV252 Still undefined -- -- 
HCV CD81, LDL Y Y 
HSV253-256 Heparan Sulfate; HVEM, 
Nectin-1; Nectin-2 
Y Y 
HIV55 CD4; CCR5; CXCR4 Y Y 




identified as HIV components (e.g., syntenin-1, HSP90, ezrin, tetraspanins, and annexin 
A2) are also found in mass spectrometry analyses from other virions (such as Newcastle 
disease virus, PRRSV, and influenza virus).259-261 It must be noted, however, that these 
similarities are merely thought-provoking and it remains to be shown whether there are 
commonalities between enveloped viruses that drive them to target similar host processes 
during egress and entry. 
 
As there is a signal that fission and fusion selective pressures appear to be shared across 
multiple viruses, we can speculate that greater insight could impact treatment for many 
viral infections. Of course, as these processes are also vital for proper cellular function, 
targeting these processes directly many not be clinically viable. Targeting viral-host 
protein interactions; however, may be a reasonable goal. Considering the implications of 
primary interactions between viral proteins and host proteins and the impact on viral 
budding and membrane fusion, identifying the interactions that drive the viral phenotype 
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